Quarterly report · Q3
7733.TEDINET S100SVFE
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥675.7bn | 2023-04-01 → 2023-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥239.1bn | 2023-10-01 → 2023-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥881.9bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥641.5bn | 2022-04-01 → 2022-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥224.5bn | 2022-10-01 → 2022-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥39.0bn | 2023-04-01 → 2023-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥34.2bn | 2023-10-01 → 2023-12-31d | Cons. | Operating profit loss IFRS |
| Operating income | ¥142.6bn | 2022-04-01 → 2022-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥49.0bn | 2022-10-01 → 2022-12-31d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥33.0bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥34.0bn | 2023-10-01 → 2023-12-31d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥182.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥139.4bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥50.0bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥235.2bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥18.9bn | 2023-10-01 → 2023-12-31d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥143.4bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥108.2bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥41.4bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥235.6bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥18.9bn | 2023-10-01 → 2023-12-31d | Cons. | Profit loss IFRS |
| Net income | ¥108.4bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥41.4bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss IFRS |
| Total assets | ¥1.47T | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥1.51T | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.39T | at 2022-12-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥718.2bn | at 2023-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥867.5bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥749.9bn | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥641.2bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥605.6bn | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥511.4bn | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥749.9bn | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥640.1bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥604.5bn | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥348.6bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥169.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.5bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥211.3bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | −¥12.9bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥98.5bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥54.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | ¥391.4bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥58.4bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥37.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥240.8bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥143.2bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥112.4bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥191.59 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥15.84 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥113.22 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥85.12 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥32.64 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥191.15 | 2023-04-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥15.81 | 2023-10-01 → 2023-12-31d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥113.08 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥85.04 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥32.6 | 2022-10-01 → 2022-12-31d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 51.1% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 42.4% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 43.4% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 10
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | −¥29.3bn |
| jpcrp040300-q3r_E02272-000Endoscopic Solutionsreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥83.6bn |
| jpcrp040300-q3r_E02272-000Otherreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥971m |
| jpcrp040300-q3r_E02272-000Therapeutic Solutionsreportable segment | segment profit | 2023-04-01 → 2023-12-31 | −¥16.2bn |
| —segment total | segment profit | 2023-04-01 → 2023-12-31 | ¥68.4bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥15.3bn |
| jpcrp040300-q3r_E02272-000Endoscopic Solutionsreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥110.7bn |
| jpcrp040300-q3r_E02272-000Otherreportable segment | segment profit | 2022-04-01 → 2022-12-31 | −¥917m |
| jpcrp040300-q3r_E02272-000Therapeutic Solutionsreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥48.1bn |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥157.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 747
| Item | Context | Value | Unit |
|---|---|---|---|
| Net increase decrease in cash and cash equivalents IFRS | Prior1YTDDuration | -91249000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | CurrentYTDDuration | 143060000000 | JPY |
| Cash and cash equivalents if different from bs balance IFRS | Prior2YearInstant | 302572000000 | JPY |
| Cash and cash equivalents if different from bs balance IFRS | Prior1YearInstant | 205512000000 | JPY |
| Cash and cash equivalents if different from bs balance IFRS | Prior1QuarterInstant | 211323000000 | JPY |
| Cash and cash equivalents if different from bs balance IFRS | CurrentQuarterInstant | 348572000000 | JPY |
| Sales to external customers IFRS | Prior1YTDDuration_jpcrp040300-q3r_E02272-000EndoscopicSolutionsReportableSegmentMember | 398990000000 | JPY |
| Sales to external customers IFRS | Prior1YTDDuration_jpcrp040300-q3r_E02272-000TherapeuticSolutionsReportableSegmentMember | 233942000000 | JPY |
| Sales to external customers IFRS | Prior1YTDDuration_jpcrp040300-q3r_E02272-000OtherReportableSegmentMember | 8613000000 | JPY |
| Sales to external customers IFRS | Prior1YTDDuration_ReportableSegmentsMember | 641545000000 | JPY |
| Sales to external customers IFRS | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Sales to external customers IFRS | Prior1YTDDuration | 641545000000 | JPY |
| Intersegment sales IFRS | Prior1YTDDuration_jpcrp040300-q3r_E02272-000EndoscopicSolutionsReportableSegmentMember | － | JPY |
| Intersegment sales IFRS | Prior1YTDDuration_jpcrp040300-q3r_E02272-000TherapeuticSolutionsReportableSegmentMember | － | JPY |
| Intersegment sales IFRS | Prior1YTDDuration_jpcrp040300-q3r_E02272-000OtherReportableSegmentMember | 211000000 | JPY |
| Intersegment sales IFRS | Prior1YTDDuration_ReportableSegmentsMember | 211000000 | JPY |
| Intersegment sales IFRS | Prior1YTDDuration_ReconcilingItemsMember | -211000000 | JPY |
| Intersegment sales IFRS | Prior1YTDDuration | － | JPY |
| Net sales IFRS | Prior1YTDDuration_jpcrp040300-q3r_E02272-000EndoscopicSolutionsReportableSegmentMember | 398990000000 | JPY |
| Net sales IFRS | Prior1YTDDuration_jpcrp040300-q3r_E02272-000TherapeuticSolutionsReportableSegmentMember | 233942000000 | JPY |
| Net sales IFRS | Prior1YTDDuration_jpcrp040300-q3r_E02272-000OtherReportableSegmentMember | 8824000000 | JPY |
| Net sales IFRS | Prior1YTDDuration_ReportableSegmentsMember | 641756000000 | JPY |
| Net sales IFRS | Prior1YTDDuration_ReconcilingItemsMember | -211000000 | JPY |
| Net sales IFRS | Prior1YTDDuration | 641545000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q3r_E02272-000EndoscopicSolutionsReportableSegmentMember | 110703000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q3r_E02272-000TherapeuticSolutionsReportableSegmentMember | 48116000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q3r_E02272-000OtherReportableSegmentMember | -917000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_ReportableSegmentsMember | 157902000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_ReconcilingItemsMember | -15330000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration | 142572000000 | JPY |
| Finance income IFRS | Prior1YTDDuration | 2983000000 | JPY |
| Finance costs IFRS | Prior1YTDDuration | 6185000000 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | 139370000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration_jpcrp040300-q3r_E02272-000EndoscopicSolutionsReportableSegmentMember | 490000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration_jpcrp040300-q3r_E02272-000TherapeuticSolutionsReportableSegmentMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration_jpcrp040300-q3r_E02272-000OtherReportableSegmentMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration_ReportableSegmentsMember | 490000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration | 490000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration_jpcrp040300-q3r_E02272-000EndoscopicSolutionsReportableSegmentMember | 29271000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration_jpcrp040300-q3r_E02272-000TherapeuticSolutionsReportableSegmentMember | 14513000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration_jpcrp040300-q3r_E02272-000OtherReportableSegmentMember | 887000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration_ReportableSegmentsMember | 44671000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration_ReconcilingItemsMember | 4436000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration | 49107000000 | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration_jpcrp040300-q3r_E02272-000EndoscopicSolutionsReportableSegmentMember | 907000000 | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration_jpcrp040300-q3r_E02272-000TherapeuticSolutionsReportableSegmentMember | 401000000 | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration_jpcrp040300-q3r_E02272-000OtherReportableSegmentMember | 3000000 | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration_ReportableSegmentsMember | 1311000000 | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |